245 related articles for article (PubMed ID: 29659887)
1. Homeostasis Model Assessment of Insulin Resistance and Survival in Patients With Diabetes and Acute Coronary Syndrome.
Stähli BE; Nozza A; Schrieks IC; Buse JB; Malmberg K; Mellbin L; Neal B; Nicholls SJ; Rydén L; Svensson A; Wedel H; Weichert A; Lincoff AM; Grobbee DE; Tardif JC; Schwartz GG
J Clin Endocrinol Metab; 2018 Jul; 103(7):2522-2533. PubMed ID: 29659887
[TBL] [Abstract][Full Text] [Related]
2. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.
Lincoff AM; Tardif JC; Schwartz GG; Nicholls SJ; Rydén L; Neal B; Malmberg K; Wedel H; Buse JB; Henry RR; Weichert A; Cannata R; Svensson A; Volz D; Grobbee DE;
JAMA; 2014 Apr; 311(15):1515-25. PubMed ID: 24682069
[TBL] [Abstract][Full Text] [Related]
3. Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus.
Wolsk E; Claggett B; Pfeffer MA; Diaz R; Dickstein K; Gerstein HC; Lawson FC; Lewis EF; Maggioni AP; McMurray JJV; Probstfield JL; Riddle MC; Solomon SD; Tardif JC; Køber L
J Am Heart Assoc; 2017 May; 6(6):. PubMed ID: 28554908
[TBL] [Abstract][Full Text] [Related]
4. Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome.
Schrieks IC; Nozza A; Stähli BE; Buse JB; Henry RR; Malmberg K; Neal B; Nicholls SJ; Rydén L; Mellbin L; Svensson A; Wedel H; Weichert A; Lincoff AM; Tardif JC; Grobbee DE; Schwartz GG
Diabetes Care; 2018 Aug; 41(8):1792-1800. PubMed ID: 29903845
[TBL] [Abstract][Full Text] [Related]
5. Predictors of mortality in hospital survivors with type 2 diabetes mellitus and acute coronary syndromes.
Savonitto S; Morici N; Nozza A; Cosentino F; Perrone Filardi P; Murena E; Morocutti G; Ferri M; Cavallini C; Eijkemans MJ; Stähli BE; Schrieks IC; Toyama T; Lambers Heerspink HJ; Malmberg K; Schwartz GG; Lincoff AM; Ryden L; Tardif JC; Grobbee DE
Diab Vasc Dis Res; 2018 Jan; 15(1):14-23. PubMed ID: 29052439
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial.
Lincoff AM; Tardif JC; Neal B; Nicholls SJ; Rydén L; Schwartz GG; Malmberg K; Buse JB; Henry RR; Wedel H; Weichert A; Cannata R; Grobbee DE
Am Heart J; 2013 Sep; 166(3):429-34. PubMed ID: 24016490
[TBL] [Abstract][Full Text] [Related]
7. NT-proBNP by Itself Predicts Death and Cardiovascular Events in High-Risk Patients With Type 2 Diabetes Mellitus.
Malachias MVB; Jhund PS; Claggett BL; Wijkman MO; Bentley-Lewis R; Chaturvedi N; Desai AS; Haffner SM; Parving HH; Prescott MF; Solomon SD; De Zeeuw D; McMurray JJV; Pfeffer MA
J Am Heart Assoc; 2020 Oct; 9(19):e017462. PubMed ID: 32964800
[TBL] [Abstract][Full Text] [Related]
8. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults.
Kistorp C; Raymond I; Pedersen F; Gustafsson F; Faber J; Hildebrandt P
JAMA; 2005 Apr; 293(13):1609-16. PubMed ID: 15811980
[TBL] [Abstract][Full Text] [Related]
9. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease.
Bibbins-Domingo K; Gupta R; Na B; Wu AH; Schiller NB; Whooley MA
JAMA; 2007 Jan; 297(2):169-76. PubMed ID: 17213400
[TBL] [Abstract][Full Text] [Related]
10. Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial.
Schwartz GG; Nicholls SJ; Toth PP; Sweeney M; Halliday C; Johansson JO; Wong NCW; Kulikowski E; Kalantar-Zadeh K; Ginsberg HN; Ray KK
Cardiovasc Diabetol; 2021 Jun; 20(1):125. PubMed ID: 34158057
[TBL] [Abstract][Full Text] [Related]
11. Post-Discharge Worsening Renal Function in Patients with Type 2 Diabetes and Recent Acute Coronary Syndrome.
Morici N; Savonitto S; Ponticelli C; Schrieks IC; Nozza A; Cosentino F; Stähli BE; Perrone Filardi P; Schwartz GG; Mellbin L; Lincoff AM; Tardif JC; Grobbee DE
Am J Med; 2017 Sep; 130(9):1068-1075. PubMed ID: 28344139
[TBL] [Abstract][Full Text] [Related]
12. The haemoglobin glycation index as predictor of diabetes-related complications in the AleCardio trial.
van Steen SC; Schrieks IC; Hoekstra JB; Lincoff AM; Tardif JC; Mellbin LG; Rydén L; Grobbee DE; DeVries JH;
Eur J Prev Cardiol; 2017 May; 24(8):858-866. PubMed ID: 28186441
[TBL] [Abstract][Full Text] [Related]
13. Relationship between insulin resistance, coronary plaque, and clinical outcomes in patients with acute coronary syndromes: an analysis from the PROSPECT study.
Farhan S; Redfors B; Maehara A; McAndrew T; Ben-Yehuda O; De Bruyne B; Mehran R; Vogel B; Giustino G; Serruys PW; Mintz GS; Stone GW
Cardiovasc Diabetol; 2021 Jan; 20(1):10. PubMed ID: 33413366
[TBL] [Abstract][Full Text] [Related]
14. Serial Measurement of Natriuretic Peptides and Cardiovascular Outcomes in Patients With Type 2 Diabetes in the EXAMINE Trial.
Jarolim P; White WB; Cannon CP; Gao Q; Morrow DA
Diabetes Care; 2018 Jul; 41(7):1510-1515. PubMed ID: 29848776
[TBL] [Abstract][Full Text] [Related]
15. EuroSCORE II and N-terminal pro-B-type natriuretic peptide for risk evaluation: an observational longitudinal study in patients undergoing coronary artery bypass graft surgery.
Holm J; Vidlund M; Vanky F; Friberg Ö; Håkanson E; Walther S; Svedjeholm R
Br J Anaesth; 2014 Jul; 113(1):75-82. PubMed ID: 24727704
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular Mortality in Chest Pain Patients: Comparison of Natriuretic Peptides With Novel Biomarkers of Cardiovascular Stress.
Sinning C; Ojeda F; Zeller T; Zengin E; Rupprecht HJ; Lackner KJ; Bickel C; Blankenberg S; Schnabel RB; Westermann D
Can J Cardiol; 2016 Dec; 32(12):1470-1477. PubMed ID: 27568502
[TBL] [Abstract][Full Text] [Related]
17. Statin treatment is associated with a negative correlation between NT-proBNP and insulin resistance in patients without history of heart failure.
Wang JS; Lee CL; Lee WJ; Lee IT; Lin SY; Lee WL; Liang KW; Sheu WH
Clin Chim Acta; 2016 Aug; 459():84-88. PubMed ID: 27221204
[TBL] [Abstract][Full Text] [Related]
18. The value of NT-proBNP in early risk stratification of acute coronary syndromes.
Almeida R; Mariano L; Gavina C; Pinho T; Vasconcelos M; Ferreira A; Maciel MJ; Gonçalves FR
Rev Port Cardiol; 2006 Jan; 25(1):71-5. PubMed ID: 16623357
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52) Trial.
Fanola CL; Morrow DA; Cannon CP; Jarolim P; Lukas MA; Bode C; Hochman JS; Goodrich EL; Braunwald E; O'Donoghue ML
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29066436
[TBL] [Abstract][Full Text] [Related]
20. Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes.
Erdmann E; Califf R; Gerstein HC; Malmberg K; Ruilope L; Schwartz GG; Wedel H; Volz D; Ditmarsch M; Svensson A; Bengus M
Am Heart J; 2015 Jul; 170(1):117-22. PubMed ID: 26093872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
